DalsnaFinance › Analyst accuracy › UBS › VRTX target
UBS raises Vertex stock price target to $615 on kidney drug trial
UBS raised its price target on Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to $615 from $585
A fact about what UBS published, as reported by Investing.com, not a recommendation from Dalsna Finance; UBS is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.